Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Short-term Investments (2016 - 2018)

Cumberland Pharmaceuticals' Short-term Investments history spans 7 years, with the latest figure at $8.3 million for Q4 2018.

  • For Q4 2018, Short-term Investments rose 77.44% year-over-year to $8.3 million; the TTM value through Dec 2018 reached $8.3 million, up 77.44%, while the annual FY2018 figure was $8.3 million, 77.44% up from the prior year.
  • Short-term Investments for Q4 2018 was $8.3 million at Cumberland Pharmaceuticals, up from $4.7 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $15.6 million in Q4 2016 and bottomed at $4.7 million in Q4 2017.
  • The 5-year median for Short-term Investments is $14.6 million (2015), against an average of $11.6 million.
  • The largest annual shift saw Short-term Investments crashed 70.09% in 2017 before it surged 77.44% in 2018.
  • A 5-year view of Short-term Investments shows it stood at $14.8 million in 2014, then dropped by 1.87% to $14.6 million in 2015, then increased by 7.26% to $15.6 million in 2016, then plummeted by 70.09% to $4.7 million in 2017, then surged by 77.44% to $8.3 million in 2018.
  • Per Business Quant, the three most recent readings for CPIX's Short-term Investments are $8.3 million (Q4 2018), $4.7 million (Q4 2017), and $15.6 million (Q4 2016).